Quarterly report pursuant to sections 13 or 15(d)

Convertible Instruments - Additional Information (Detail)

v2.4.0.8
Convertible Instruments - Additional Information (Detail) (USD $)
3 Months Ended 6 Months Ended 12 Months Ended 121 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2013
Nov. 30, 2012
Nov. 30, 2013
Nov. 30, 2012
May 31, 2013
Nov. 30, 2013
Nov. 30, 2013
Investor
May 31, 2013
Investor
May 31, 2013
Minimum
Nov. 30, 2013
Minimum
Investor
May 31, 2013
Minimum
Investor
May 31, 2013
Maximum
Nov. 30, 2013
Maximum
Investor
May 31, 2013
Maximum
Investor
Nov. 30, 2013
US Phase III trial
Nov. 30, 2013
US new drug application approval by the FDA
Nov. 30, 2013
Convertible Note One
Note
Nov. 30, 2013
Convertible Note Two
Note
Nov. 30, 2013
Convertible Note Three
Note
Nov. 30, 2013
Convertible Note Four
May 31, 2010
Series B convertible preferred stock
Nov. 30, 2013
Series B convertible preferred stock
May 31, 2010
Common Stock
Apr. 30, 2010
Common Stock
Class of Stock [Line Items]                                                
Preferred Stock, Shares issued 95,100   95,100   95,100 95,100                             400,000      
Preferred Stock, Share issuance price $ 1.30   $ 1.30     $ 1.30                             $ 5.00      
Cash proceeds                                         $ 2,009,000      
Preferred stock shares outstanding 95,100   95,100   95,100 95,100                               95,100    
Number of common shares issued upon conversion of preferred stock                                             10  
Convertible note conversion price per share                             $ 0.75 $ 0.65     $ 0.65 $ 0.75     $ 0.50  
Common stock shares authorized for issuance 100,000,000   100,000,000   100,000,000 100,000,000                                   100,000,000
Constructive dividend to Preferred stock holders     6,000,000                                          
Liquidation preference on common shares 5.00   5.00     5.00                                    
Dividends are payable to preferred stock holders     $ 0.25                                          
Face amount of notes 1,200,000   1,200,000   6,588,250 1,200,000                                    
Convertible note, conversion amount                             4,521,250 100,000                
Number of notes converted                                 6 1 2          
Convertible notes term                                 6 months 6 months 6 months 3 years        
Principal amount of notes     2,350,000   567,000                       850,000 250,000 380,000 1,120,000        
Common stock issued upon conversion of notes                                 1,307,692   594,384 1,493,333        
Warrants to purchase shares of common stock                                 659,486   292,307          
Warrants exercise price per share 0.75   0.75     0.75         0.50     2.00     0.75   0.75          
Aggregate principal amount plus accrued but unpaid interest                                     6,351          
Exercisable warrants, expire period                                     5 years          
Interest expense associated with conversion inducement     193,160     193,160                         193,000          
Earliest date for repayment of principal on remaining notes     Feb. 01, 2014                                          
Latest date for repayment of principal on remaining notes     Mar. 06, 2016                                          
Interest rate on convertible notes                 5.00%     10.00%                        
Interest on convertible notes payment start date             Apr. 01, 2013                                  
Common stock warrant term                   2 years     3 years                      
Warrants to purchase common shares, shares               9,451,056                                
Amortization expense $ 1,595,000 $ 0 $ 3,047,000 $ 257,300   $ 4,756,000